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Original Article
Self-monitoring of blood glucose (SMBG) is a major com-
ponent of diabetes management; it provides information 
about current glycemic status, which is necessary to trigger 
immediate treatment adjustments to improve glucose con-
trol. Its incorporation into daily practice has represented an 
important step forward in diabetes care, because it helps to 
optimize treatment outcomes1-3 and promotes the active par-
ticipation of patients in the control and treatment of their dis-
ease, the development of self-confidence, and motivation.4,5 
Consequently, test strip use for SMBG has risen sharply over 
the past decade,6 leading to an increase in the cost of the 
metabolic control of people with diabetes.7 In fact, the cost 
of test strips can represent up to 41.6% of the total pharmacy 
cost.8 On the other hand, reported evidence has shown that 
SMBG would facilitate the achievement of treatment goals 
and decrease the costs of care.9,10
While the benefits of SMBG in people with type 1 
(T1DM) or type 2 diabetes (T2DM) treated with insulin are 
widely accepted, its performance in patients with T2DM 
treated with oral antidiabetic drugs (OAD) or lifestyle 
changes has been seriously challenged.11 Given the high cost 
of the current T2DM care and the fact that its prevalence 
continues to grow worldwide, many efforts have been made 
to determine whether economic support to SMBG in non-
insulin-treated T2DM patients is justified and effectively 
applied. Despite these concerns, test strip use in real world 
conditions and its financial implications have not been exten-
sively explored. The issue is important particularly in devel-
oping countries, where health budgets are not always 
sufficient to cope with the constant demand of care for costly 
chronic diseases such as diabetes. However, neither the 
affordability of SMBG cost in these countries nor the 
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Abstract
Background: Although test strips for self-monitoring of blood glucose (SMBG) represent around 50% of diabetes treatment 
cost in Argentina, little is known about their current use and relationship with different types of treatment. We therefore 
aimed to estimate the current use of test strips and identify the major use drivers and the percentage they represent of total 
prescription costs in 2 entities of the social security system (SSS) of Argentina. 
Methods: Observational retrospective study measuring test strip prescriptions delivered by pharmacies from the province 
of Buenos Aires (8115 records collected during 3 months provided by the Colegio de Farmacéuticos de la Provincia de 
Buenos Aires) of affiliates with type 2 diabetes (T2DM) from 2 large entities of the SSS system. 
Results: The average monthly test strips/patient used for SMBG was 97.5 ± 70.1. This number varied according to treatment: 
monotherapy with oral antidiabetic drugs (OAD) < combined OAD therapy < insulin treatment. Test strips represented a 
higher percentage of the total prescription cost in people under OAD monotherapy (84.6%) and lower in those with insulin 
analogs (46.9%). 
Conclusions: In our population, the type of hyperglycemia treatment was the main driver of test strip use for SMBG and 
its impact on the total prescription cost depends on the kind of such treatment. Since it has been shown that patients’ 
education and prescription audit can optimize test strip use and treatment outcomes, implementation of such strategies 
could appropriately support, optimize, and reduce ineffective test strip use in people with T2DM.
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implementation of any policy to cover its cost can be estab-
lished when there are no current use and cost data.
In an attempt to provide such evidence, we currently stud-
ied test strip use for SMBG and its relative impact on total 
prescription cost (OAD and insulin) to treat people with dia-
betes in the social security system (SSS) of Argentina.
Methods
We performed an observational retrospective study collect-
ing information from prescription data of 2 entities belong-
ing to the SSS, provided by the Colegio de Farmacéuticos de 
la Provincia de Buenos Aires (COLFARMA).
COLFARMA systematically records online all the test 
strip prescriptions delivered by the pharmacies of the prov-
ince of Buenos Aires to the SSS affiliates at a variable out-of-
pocket cost. This organization provided 8297 anonymous 
registries of affiliates from 2 large entities of the SSS; the 
data included drug and test strip prescriptions collected in the 
province during 3 months (February to April 2012). Before 
starting the statistical analysis of these data, we reviewed the 
whole database searching for atypical values (number of test 
strips beyond a reasonable daily use and based on an objec-
tive cut-off value). To identify those values, we applied a 
common statistical model using the interquartile ranges 
(IQRs), defining an outlier as any observation outside the 
range [Q1 – (k × IQR); Q3 + (k × IQR)], with Q1, Q3 = first 
and third quartiles, IQR = Q3 − Q1. We set k = 3 to only 
remove “extreme” outliers in the data. Accordingly, we con-
sidered as atypical utilization more than 300 test strips per 
month for people treated with insulin, and more than 200 
strips per month for those treated only with OADs. These 
values were considered as the consequence of data loading 
mistakes. Using this criterion, we excluded 182 records, thus 
including 8115 records in the final statistical analysis.
Statistical analyses were done using the Statistical 
Package for Social Sciences version 15 (SPSS Inc, Chicago, 
IL, USA). Descriptive statistics are presented as percentages 
with 95% confidence intervals (CIs) and mean ± standard 
deviation (SD). Group comparisons for continuous variables 
were performed by ANOVA, Student’s t test, Mann–Whitney 
U test and Kruskal–Wallis test according to the data distribu-
tion profile. Chi-square test was performed for proportions. 
The level of significance was established at P ≤ .05.
We also estimated the impact of test strip use on total pre-
scription cost for hyperglycemia treatment. For that purpose, 
we designed a model that represents an average of prescrip-
tions provided by COLFARMA. The monthly cost of a given 
medical prescription was estimated by micro-costing. Drug 
and test strip costs were obtained from Alfabeta.net, a private 
Internet database which is the main source of pharmaceutical 
product pricing in the Argentine market. Values are expressed 
in Argentine pesos as of December 2012.
Results
The average monthly use of test strips/person was 97.5 ± 
70.1 (Table 1); 75.4% of patients were treated with either 
insulin alone or associated with OADs. The average monthly 
test strip use was larger in people treated with insulin than in 
those treated only with OADs (P < .001). In the latter group, 
52.9% of patients were treated with a single OAD and the 
number of test strips was lower than that of patients treated 
with a combination of OAD (P < .001).
Within the group of patients treated only with insulin, 
87% used only long-acting insulin, 10% used only crystal-
line insulin, and 3% used both (basal bolus). Test strip use in 
the last group was significantly lower than that of patients 
using only long-acting insulin (P = .042) (Table 1).
People treated with a combination of insulin plus OAD used 
significantly less test strips than those treated only with insulin 
(P < .001; Figure 1), regardless of the type of insulin used.
Impact of Test Strip on the Total Cost of the 
Medical Prescription
Test strips for SMBG represented in average 66.3% of the 
total cost of each physician prescription. This percentage 
Table 1. COLFARMA Data: Test Strip Use for SMBG According to Type of Treatment.
Mean SD Median IQR n P
DM total 97.5 70.1 67 33-133 8115 —
Treatment  
 Only OADs 70.2 46.3 67 33-100 1973 <.001*
 Insulin (with or w/o OADs) 106.3 74.1 67 50-133 6142
Only OADs  
 Monotherapy 66.2 45.0 67 33-83 1043 <.001*
 Combined therapy 74.7 47.3 67 33-100 930
 Insulin with OADs 89.0 62.5 67 33-133 1313 —
Only insulin  
 Long acting (LA) 112.0 76.2 100 67-167 4200 .037†
 Crystalline (C) 105.9 79.4 67 33-133 496
 LA + C 98.4 65.4 83 50-133 133  
DM, diabetes; IQR, interquartile range; OAD, oral antidiabetic drugs. *Student’s t test. †ANOVA.
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varied according to the type of treatment and the frequency 
of SMBG. While the highest value was achieved with OAD 
monotherapy (84.6%), it decreased as a function of the num-
ber of drugs used to treat hyperglycemia, reaching the lowest 
in cases of intensified insulin therapy with analogs (46.9%; 
Table 2).
Discussion
This study analyzed the use of test strips for SMBG in a 
group of people with diabetes whose care and treatment is 
covered by 2 different entities of the SSS in Argentina. 
Results show that the monthly use of SMBG test strips was 
significantly associated with the type of hyperglycemia treat-
ment considered: while it was higher in people receiving 
insulin, followed by those treated with a combination of 
OAD, the lower figures corresponded to people receiving a 
single OAD. Thus, under our study conditions, type of treat-
ment was apparently an important driver of the SMBG fre-
quency and test strip use pattern.
SMBG is considered a core component of effective diabe-
tes self-management of either T1DM or insulin-treated 
T2DM patients. Accordingly, the 2013 American Diabetes 
Association (ADA) guidelines for SMBG frequency state 
that “patients on intensive insulin regimens might perform 
SMBG at least before meals and snacks, as well as occasion-
ally after meals, at bedtime, before exercise and before criti-
cal tasks, when hypoglycemia is suspected and after treating 
hypoglycemia until normoglycemia is achieved.”12 This rec-
ommendation means that these patients might frequently—
though not regularly—perform 8 or more daily tests. These 
figures are far from those currently recorded in our insulin-
treated patients.
On account of the ADA and other recommendations, the 
use and frequency of SMBG has progressively increased in 
the last decade, facilitating diabetes self-management and 
patient empowerment, but also increasing its economic cost.6 
While there is general agreement regarding SMBG benefits 
for people with T1DM or T2DM treated with insulin, there 
are divergent views on such benefits in people with T2DM 
on oral treatment. Three recent reviews have shown mixed 
opinions on the issue; 1 of them does not find any benefit,11 
and the other 2 do, but only under certain circumstances, that 
is, SMBG is useful in non-insulin-treated T2DM patients 
only when the glucose information is understood correctly 
and accurately interpreted by the patient, and the process 
results in therapy adjustments.13,14 A similar position was 
adopted by the International Diabetes Federation (IDF) and 
Figure 1. COLFARMA test strip use according to type of treatment. Values represent the mean ± SD. Number of cases in brackets. 
Error bars represent standard error of the mean (SEM). †P < .001 (ANOVA; F statistic = 178.97) between all groups. *Statistically 
significant (P < .001) between the indicated groups.
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the Canadian Diabetes Association (CDA) in their guidelines 
for SMBG.15,16 The ADA also recommends that clinicians 
must not only educate these people on how to interpret their 
SMBG data, but they should also reevaluate the ongoing 
need for and frequency of SMBG at each routine visit.12 
Therefore, most organizations share the concept that it is 
worth using SMBG in people with T2DM not treated with 
insulin only when it results in a proactive therapeutic adjust-
ment, that is, when patients have been educated to make their 
own appropriate therapeutic decisions. Unfortunately, it has 
been shown that when blood glucose is high or low, many 
patients do nothing, and only some of them take an active 
attitude toward its correction.17 In those cases, SMBG 
increases the cost of care, but it does not necessarily help to 
achieve treatment targets.
A lower SMBG frequency has been recorded among peo-
ple paying higher out-of-pocket expenditures for test strips 
or having limited access to them.18,19 This would not be the 
case in our study because we did not find any significant 
association between these 2 variables, despite the different 
percentage of coverage within the SSS.
In brief, our study provides important data to estimate the 
cost and the affordability of SMBG potential full coverage 
either in entities of our SSS or from other countries with simi-
lar health care characteristics. In addition, and on account of 
previous reports, it could serve to associate SMBG to patient 
education and prescription audit to optimize their favorable 
impact on treatment outcomes and to decrease ineffective test 
strip use.20 Further studies are necessary to obtain a complete 
view of the impact of SMBG on treatment outcomes and 
establish a reasonable coverage policy based on real world 
needs and benefits of its use in developing countries.
Limitations
Although our results provide information that was not previ-
ously available, they should be considered with caution 
because (1) the data analyzed were obtained from an obser-
vational retrospective study performed in a population from 
2 entities of our SSS rather than from a population-based 
study, and (2) as previously mentioned, data included only 
test strip use and type of diabetes, but not clinical or labora-
tory results. Thus, it was not possible to evaluate the impact 
of SMBG on treatment goal achievement.
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Table 2. Impact of Test Strip Use for SMBG on the Total Cost of a Given Treatment Prescription.
Prescription Monthly cost (Argentine pesos) Test strips (%)
Metformin (850 mg × 2)—Glucophage 850®
Strips—Accu-Chek Performa 25® (COLFARMA: 66.2)
90.6
497.3
84.6
Total 587.9  
Metformin (850 mg × 2)—Glucophage 850®
Gliclazide (80 mg 2/day)—Diamicron®
Strips—Accu-Chek Performa 25® (COLFARMA: 74.7)
Total
90.6
106.0
561.1
757.7
74.0
DPP4i + Metformin (50/850 mg 2/day)—Janumet®
Strips—Accu-Chek Performa 25® (COLFARMA: 74.7)
Total
336.1
561.1
897.2
62.5
NPH Insulin (30 IU/day)—Insulatard®
Strips—Accu-Chek Performa 50® (COLFARMA: 106.3)
Total
187.6
632.3
819.9
77.1
Insulin Analog (30 IU/day)—Levemir®
Strips—Accu-Chek Performa 50® (COLFARMA: 106.3)
Total
562.5
632.3
1194.8
52.9
Insulin Analog—Basal (20 IU/day)—Levemir®
Insulin Analog—Bolus (20 IU/day)—Humalog®
Strips—Accu-Chek Performa 50® (COLFARMA: 106.3)
Total
375.0
342.0
632.3
1349.3
46.9
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